Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia
2024-515970-28-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in dystonic tremor and dystonia, sponsored by Radboud University Medical Center. Planned start Nov 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
dystonic tremordystonia
Beyond the preview
Go deeper on 2024-515970-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515970-28-00.